Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia) (UNAL MALARIA)
Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, the Standard Treatment Recommended by the Ministry of the Social Protection in Colombia for the Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia)
Sponsor: Sanofi Pasteur, a Sanofi Company
A PHASE4 clinical study on P. Falciparum Malaria, this trial is completed. The trial is conducted by Sanofi Pasteur, a Sanofi Company and has accumulated 3 data snapshots since 2008. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
3 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE4
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi Pasteur, a Sanofi Company
- Universidad Nacional de Colombia
For direct contact, visit the study record on ClinicalTrials.gov .